Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.



    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DOHH-2 NFXP[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[4fVRKSzVyPUmuN|U3QDlizszN MnT6V2FPT0WU
no-10 MorKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVuzZYNQUUN3ME25MlkxOzlizszN NW\EfZJ5W0GQR1XS
LS-513 M3nkbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrjNVBCUUN3ME2xNU4{PTR5IN88US=> NEnNfnlUSU6JRWK=
8-MG-BA NEfNbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjMTFhKSzVyPUGzMlEyOjNizszN MmLJV2FPT0WU
RPMI-8402 NYLVZZhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnG[oRKSzVyPUG1Mlg2OzdizszN NWKzZXNoW0GQR1XS
EoL-1-cell MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXeyOoduUUN3ME2xPE42QTR6IN88US=> MVHTRW5ITVJ?
NALM-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2iwZmlEPTB;MUmuNFE3PyEQvF2= MnLjV2FPT0WU
SR NEnvbYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJ|Lk[3NVUh|ryP NX;jRohtW0GQR1XS
697 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoK2TWM2OD1{Nj62NVU2KM7:TR?= Ml;BV2FPT0WU
COLO-829 NWHKTow{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rERWlEPTB;Mk[uPFQ5OyEQvF2= M2TsV3NCVkeHUh?=
EVSA-T NHz5ZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTJ5LkW1OlEh|ryP M1;PUnNCVkeHUh?=
ATN-1 M{LyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HPNWlEPTB;M{GuNlMzQSEQvF2= NX3mRYdIW0GQR1XS
LAMA-84 NFm2SHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojNTWM2OD1|Mj61NlEyKM7:TR?= MnPuV2FPT0WU
NOS-1 NYC0dlc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17GXmlEPTB;M{SuNlk2PiEQvF2= MWDTRW5ITVJ?
BB30-HNC NFrle|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XLO2lEPTB;M{SuN|MxPiEQvF2= NVPEUoRzW0GQR1XS
BC-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jWcGlEPTB;M{euPVc1PiEQvF2= MYDTRW5ITVJ?
IST-SL2 M3yzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1r1OmlEPTB;M{iuNlI1KM7:TR?= NGHlPZRUSU6JRWK=
D-392MG M3;EZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTITWM2OD12MD6yNlE2KM7:TR?= NUHyd3Z5W0GQR1XS
no-11 M1nxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnRSmZWUUN3ME20NE42PTJzIN88US=> NGDIcGtUSU6JRWK=
A388 M2LL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjHTWM2OD12Mj61PFQ5KM7:TR?= NEfCU4JUSU6JRWK=
NTERA-S-cl-D1 NHjwbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTR{LkewO|Qh|ryP NHn2VVhUSU6JRWK=
CESS M3r3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonoTWM2OD12ND6yNlMzKM7:TR?= M1\aWXNCVkeHUh?=
RS4-11 NGfYSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnXXHpKSzVyPUS5MlA6OzhizszN M3j4T3NCVkeHUh?=
CTV-1 NXLYSoRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrMTWM2OD13MT6wO|Qh|ryP MorPV2FPT0WU
D-502MG NUHONnNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnueFE2UUN3ME21NU43OjdzIN88US=> MX;TRW5ITVJ?
ML-2 NFPn[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITuToNKSzVyPUWyMlkyQTVizszN Mlj1V2FPT0WU
SK-NEP-1 M4nDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;oTWM2OD13Mz6zPVI{KM7:TR?= MYjTRW5ITVJ?
DJM-1 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTV4LkOzPVEh|ryP M{n1W3NCVkeHUh?=
GI-1 M33H[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu2cFkyUUN3ME21Ok43OTR7IN88US=> NGHXW3dUSU6JRWK=
MV-4-11 M1vBcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZyLk[1N|gh|ryP M3z6N3NCVkeHUh?=
KE-37 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIL2R|RKSzVyPU[2MlI3PjhizszN NEXzb5NUSU6JRWK=
D-542MG M2HYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HxWmlEPTB;NkiuOFE{PSEQvF2= M3vyTHNCVkeHUh?=
MRK-nu-1 NIPWc4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTd|LkS3NFUh|ryP MVTTRW5ITVJ?
D-247MG M4Xwe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPL[m9KSzVyPUezMlU1PDJizszN MnHaV2FPT0WU
OCI-AML2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTd4LkmzOlkh|ryP MkX2V2FPT0WU
LP-1 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HZ[WlEPTB;OEKuPFc{OSEQvF2= NH;1[4tUSU6JRWK=
HCC1599 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPucI5LUUN3ME24OE4zQDN5IN88US=> Mn:zV2FPT0WU
BE-13 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVK3eVV7UUN3ME25PU4xPDd5IN88US=> M2n5enNCVkeHUh?=
GCIY MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\xTWM2OD17OT6wPVU1KM7:TR?= Mn:zV2FPT0WU
BV-173 MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFyMD6zNlUh|ryP NILDVW9USU6JRWK=
LB2518-MEL MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jodGlEPTB;MUCwMlc5QSEQvF2= MoT4V2FPT0WU
KS-1 NXf3SJlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7tcYRKSzVyPUGwNU43OzlizszN Moe5V2FPT0WU
MOLT-16 NVzRNWdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYd2lEPTB;MUC0Mlk5PiEQvF2= Mk[2V2FPT0WU
NCI-H1770 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m0TmlEPTB;MUC4Mlc5PCEQvF2= NH\FcnBUSU6JRWK=
NCI-H82 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTFzMD65O|Yh|ryP NEfKbYtUSU6JRWK=
NCCIT M{Tnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjiWG9tUUN3ME2xNVIvPTJ7IN88US=> M2PkO3NCVkeHUh?=
KALS-1 M4nIbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrpeGdIUUN3ME2xNVUvQTRzIN88US=> MV3TRW5ITVJ?
LB2241-RCC NY\wSVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnO[mxKSzVyPUGxOk43PzlizszN NGHkTVhUSU6JRWK=
EB-3 NYXQV|ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPpTWM2OD1zMkOuNFk1KM7:TR?= Mk\3V2FPT0WU
BL-70 M4nPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF{Mz6xNlch|ryP MYPTRW5ITVJ?
K-562 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTF{Nj6yOFUh|ryP M{S5SnNCVkeHUh?=
HT-144 M4rXS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDwTWM2OD1zM{OuNVY1KM7:TR?= NXvSNVNbW0GQR1XS
RPMI-8226 NXq0N2pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXQd4FKSzVyPUGzOU4xPDVizszN NGTie41USU6JRWK=
NCI-H1355 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Sy[mlEPTB;MUO1MlU5PyEQvF2= MX3TRW5ITVJ?
LXF-289 NEDIXW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vqVmlEPTB;MUO5Mlc5OSEQvF2= MY\TRW5ITVJ?
NCI-H69 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF2Mj65N|Ih|ryP NX3WPJp7W0GQR1XS
SK-MEL-1 Mmf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;GNXg1UUN3ME2xOFcvOTNizszN MWjTRW5ITVJ?
KARPAS-299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G2dmlEPTB;MUS5MlEzKM7:TR?= NVTmeGlRW0GQR1XS
GB-1 M4D4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTF2OT6zNlIh|ryP M{n5bnNCVkeHUh?=
CMK NGnrbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFf6[2dKSzVyPUG0PU42OTVizszN MlrPV2FPT0WU
MPP-89 M4\zOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{T4XGlEPTB;MUW2MlA{PSEQvF2= NGTpVGhUSU6JRWK=
KU812 NU\rN5h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;UcmZKSzVyPUG2NU46ODJizszN NWjxOWEyW0GQR1XS
NEC8 MnK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF4NT6wNlYh|ryP M2\HdnNCVkeHUh?=
KP-N-YS Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2r0OGlEPTB;MU[4MlM6PSEQvF2= MlLpV2FPT0WU
Ramos-2G6-4C10 NIfifoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF4OT65NVUh|ryP M2K1fHNCVkeHUh?=
LB647-SCLC NF2zW|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\UWY12UUN3ME2xO|UvQDR3IN88US=> Mli2V2FPT0WU
LU-139 Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zpN2lEPTB;MUe4MlAyQSEQvF2= MWnTRW5ITVJ?
QIMR-WIL M{jhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HvVmlEPTB;MUe5MlY1PiEQvF2= NIDF[GFUSU6JRWK=
NCI-H1395 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTF5OT65PVYh|ryP NV3zU2d4W0GQR1XS
NOMO-1 MmjUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jXV2lEPTB;MUiyMlg2KM7:TR?= NHracGhUSU6JRWK=
GI-ME-N MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DDVWlEPTB;MUi3Mlk3QSEQvF2= M171OnNCVkeHUh?=
KMS-12-PE NGPNfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF6OT6yO|Mh|ryP Mk\GV2FPT0WU
Daudi NEn0TnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLxZ|czUUN3ME2xPVEvOTJ6IN88US=> NGnPelFUSU6JRWK=
NCI-H2107 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jOfmlEPTB;MUmzMlc{QSEQvF2= MYnTRW5ITVJ?
SK-PN-DW NIfwdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF7ND63NVkh|ryP MlW2V2FPT0WU
MC-CAR M4TrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\nfmlEPTB;MkCyMlI2OyEQvF2= NVvuWoZEW0GQR1XS
SNB75 MojGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nwcGlEPTB;MkKxMlk1KM7:TR?= Mn73V2FPT0WU
ES4 MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLUTWM2OD1{MkOuO|g{KM7:TR?= M{T6VHNCVkeHUh?=
KARPAS-422 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTlTWM2OD1{MkiuN|UzKM7:TR?= M4j0UXNCVkeHUh?=
NCI-H1648 NWjWS3RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFT6fXNKSzVyPUKyPU41QDlizszN M2LxNnNCVkeHUh?=
ES6 M1;BTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzYbIt6UUN3ME2yN|kvPDNizszN M2XSWHNCVkeHUh?=
KNS-81-FD NEnae2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnqwTWM2OD1{NEGuNVk4KM7:TR?= NXyyXXlrW0GQR1XS
JAR MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTaTlBKSzVyPUK1Ok4zOjVizszN MlzCV2FPT0WU
NB1 Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqxTllzUUN3ME2yOlAvPTF4IN88US=> MXrTRW5ITVJ?
D-336MG Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDiRZJzUUN3ME2yOlAvPjl6IN88US=> MorWV2FPT0WU
BC-3 Mn;JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHXNY1oUUN3ME2yOlUvOTd6IN88US=> Mo\UV2FPT0WU
HCC2218 NYnYTIs5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7mTWM2OD1{Nk[uOFE2KM7:TR?= M1f1NnNCVkeHUh?=
LB1047-RCC M3:1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTJ4Nj63OVMh|ryP MXzTRW5ITVJ?
CTB-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS2eYZKSzVyPUK2PU46PzNizszN MoOzV2FPT0WU
NB7 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTxNpg4UUN3ME2yO|Eh|ryP MnfQV2FPT0WU
ST486 NXLmUG1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fYemlEPTB;Mke3MlQyOiEQvF2= NGjH[YxUSU6JRWK=
HCC1187 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLtTWM2OD1{OEKuPFEyKM7:TR?= NVjHVGtGW0GQR1XS
NCI-SNU-16 M1vzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTJ6ND6yOFgh|ryP NEKzWFRUSU6JRWK=
COR-L279 MnXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7zTWM2OD1{OUGuOVg1KM7:TR?= NHnzXJFUSU6JRWK=
U-698-M NWCzV205T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHqdYtKSzVyPUK5PE4zPDNizszN M{DPUHNCVkeHUh?=
HEL MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjoO4pKSzVyPUOwPU4yPDlizszN MUHTRW5ITVJ?
KINGS-1 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTFeodKSzVyPUOxNE43PzRizszN NHuxXmJUSU6JRWK=
KY821 NH3mVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\HTWM2OD1|M{[uOVk2KM7:TR?= Ml6yV2FPT0WU
MZ1-PC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDVfYZ1UUN3ME2zOFUvPjF6IN88US=> M3Pqe3NCVkeHUh?=
SIG-M5 M1m5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEC5NYtKSzVyPUO1PU44QDJizszN NHvWeZRUSU6JRWK=
HT NYi3fHhKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUi1cGczUUN3ME2zOlcvPzFzIN88US=> NX6ze|E1W0GQR1XS
HC-1 NGTk[VlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTxRpJsUUN3ME2zOlcvPzh5IN88US=> NEiybI1USU6JRWK=
NCI-H1694 NXvaS5ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4K0XWlEPTB;M{eyMlk{PCEQvF2= MVrTRW5ITVJ?
HAL-01 MlfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3Sc2ZKSzVyPUO3PU45OzhizszN NEnxUHBUSU6JRWK=
MZ7-mel NVfKfVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TGSmlEPTB;M{m3MlI{OyEQvF2= MojtV2FPT0WU
SIMA M4PkTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfGcpZKSzVyPUSwN{46OzNizszN NXPPNGxvW0GQR1XS
DG-75 NHKy[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDRTWM2OD12MUWuOlk5KM7:TR?= NFLzVlZUSU6JRWK=
HUTU-80 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfpN|U5UUN3ME20NVkvOTh3IN88US=> MWjTRW5ITVJ?
SH-4 Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TjNWlEPTB;NEK3MlU3PSEQvF2= NVnzbWd2W0GQR1XS
L-540 M4Tpfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33ETWlEPTB;NEOxMlA{OSEQvF2= MYPTRW5ITVJ?
NB10 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\CbYVKSzVyPUS0NU4zOzRizszN NIjFe2dUSU6JRWK=
ES1 M2nwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj4N2tKSzVyPUS1Nk44PTNizszN MVnTRW5ITVJ?
KMOE-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTR3Nj63NVEh|ryP Mnq2V2FPT0WU
RL95-2 NF73UIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3yWVdKSzVyPUS2NE4zOzdizszN M1nWUnNCVkeHUh?=
Raji M{LWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzmVolKSzVyPUS2PE4yPDNizszN MXrTRW5ITVJ?
CAS-1 MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoiwTWM2OD12N{KuNFc{KM7:TR?= NWCyfop[W0GQR1XS
Calu-6 NYOycIc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnlfIJnUUN3ME20O|UvOjZ3IN88US=> MmHoV2FPT0WU
KG-1 M3nwS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqzVlNIUUN3ME20O|gvPDRizszN NXe4eI5LW0GQR1XS
LB771-HNC M1v5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILHcGhKSzVyPUS4Nk4zOzJizszN MYDTRW5ITVJ?
ACN M1nEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoX6TWM2OD12OUOuOVk6KM7:TR?= MnPaV2FPT0WU
KM12 M4L1cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILyPGZKSzVyPUS5Ok42QDlizszN MV7TRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]


Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62


CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID